β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial.
Ana García-ÁlvarezIsabel BlancoInés García-LunarPaloma JordàJuan J Rodriguez-AriasLeticia Fernández-FrieraIsabel ZegriJorge NucheManuel Gomez-BuenoSusanna PratSandra PujadasEduard Sole-GonzalezMaria D Garcia-CossioMercedes RivasEstefanía TorrecillaDaniel PeredaJavier SanchezPablo García-PavíaJavier Segovia-CuberoJuan F DelgadoSonia MirabetValentín FusterJoan A BarberáBorja Ibañeznull nullPublished in: European journal of heart failure (2022)
SPHERE-HF is the first clinical trial to assess the potential benefit of β3 adrenergic agonists in PH. The trial was negative since mirabegron did not reduce PVR, the primary endpoint, in patients with CpcPH. On pre-specified secondary outcomes, a significant improvement in RV ejection fraction assessed by advanced cardiac imaging was found, without differences in functional class or quality of life.
Keyphrases
- ejection fraction
- clinical trial
- double blind
- phase ii
- phase iii
- heart failure
- placebo controlled
- pulmonary hypertension
- study protocol
- aortic stenosis
- acute heart failure
- left ventricular
- mycobacterium tuberculosis
- high resolution
- open label
- pulmonary artery
- squamous cell carcinoma
- mass spectrometry
- atrial fibrillation
- coronary artery disease
- phase ii study
- coronary artery
- insulin resistance
- photodynamic therapy
- skeletal muscle
- climate change
- rectal cancer